Cite
MLA Citation
Fabrice Barlesi et al.. “291 Phase Ib study of selicrelumab (CD40 agonist) in combination with atezolizumab (anti-PD-L1) in patients with advanced solid tumors.” Journal for immunotherapy of cancer, vol. 8, n.d., p. A178. http://access.bl.uk/ark:/81055/vdc_100144723771.0x000004